Navigation Links
N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
Date:3/13/2013

BOULDER, Colo., March 13, 2013 /PRNewswire/ -- N30 Pharmaceuticals, Inc. ("N30 Pharma") a leader in the development of therapeutics that target S-nitrosoglutathione reductase (GSNOR), announced today that it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis (CF).  The study is a multicenter, double-blind, randomized, placebo-controlled evaluation of ascending doses of N6022 in patients who have two copies of the F508del-CFTR mutation, the most common and serious form of CF.

The clinical study announced today is being conducted in collaboration with the Cystic Fibrosis Foundation's Therapeutics Development Network (TDN), and the lead principal investigator for the study is Scott Donaldson , M.D., at The University of North Carolina, Chapel Hill.  The first patient was dosed this week at National Jewish Health in Denver.  The primary objective of the study is to evaluate the safety of repeat doses of N6022.  Secondary and exploratory objectives include the evaluation of N6022 serum levels, lung function, and other markers of disease activity in CF.

"We are indebted to the cystic fibrosis clinicians and nurses who have given us such valuable advice, to the members of the TDN who have been instrumental in getting this first trial started, and to the patients who will be volunteering for participation. With this first trial, we look forward to paving the way to a new class of therapy for cystic fibrosis," said Charles Scoggin , M.D., President and Chief Executive Officer of N30 Pharma.

About Cystic FibrosisCystic fibrosis is the most common, life-threatening, genetic disease of Caucasians, affecting approximately 30,000 people in the United States and 70,000 people worldwide.  Approximately 48% of the total CF patient population, in the United States, have two copies of the F508del mutation, and an additional 39% of the total CF patient population have one copy of the F508del mutation.

CF is characterized by a defect in the chloride channel of human cells.  This channel, known as the "cystic fibrosis transmembrane conductance regulator", or CFTR, is critical for adequate water coating, or "hydration" in airways and other organs of the body. As a consequence of a mutation in the gene for CFTR, F508del-CFTR, patients produce a form of CFTR that is broken down and discarded in the cells of the body.  N30 Pharma's new drugs aim to rescue the damaged CFTR, decrease inflammation, and restore proper hydration to critical organs, particularly the lung. 

About N6022N6022 is the first of a novel class of N30 Pharma's drugs aimed at conservation of S-nitrosoglutathione (GSNO) a key, endogenous, signaling molecule that has been shown to be reduced in cystic fibrosis patients.  N30 Pharma's drugs restore GSNO levels by inhibiting GSNOR, the enzyme in the body that breaks down GSNO.

N30 Pharma's GSNOR inhibitors have dual effects in cystic fibrosis.  First, in experimental models of cystic fibrosis, they rescue or "correct" the abnormal chloride channel function that causes the thick, tenacious secretions of the lung and other organs characteristic of cystic fibrosis.  Secondly, they are potently anti-inflammatory.  This is potentially important because inflammation, particularly of the lung, is the cause of major morbidity in CF patients.

About N30 Pharmaceuticals, Inc.N30 Pharma is a privately held, clinical stage, biopharmaceutical company headquartered in Boulder, Colorado. It is the first company to discover and develop small molecules targeting GSNOR.  In addition to N6022, an injectable formulation, N30 Pharma is rapidly advancing an oral dosage form, N91115, through preclinical testing and IND submission.  Clinical trials of N91115 are targeted to begin in the first half of 2014.

N30 Pharma is dedicated to making a difference in the lives of patients with cystic fibrosis and their families.  N30 Pharma ContactsEmail: info@N30Pharma.com   Janice TrohaCharles Scoggin, MD EVP, Product DevelopmentCEOand Regulatory Affairs(720) 945 7721(720) 945 7714
'/>"/>

SOURCE N30 Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
Breaking Medicine Technology:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):